{"nctId":"NCT04469465","briefTitle":"Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)","startDateStruct":{"date":"2020-12-16","type":"ACTUAL"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria"],"count":86,"armGroups":[{"label":"Danicopan + C5 Inhibitor","type":"EXPERIMENTAL","interventionNames":["Drug: Danicopan","Drug: C5 Inhibitor"]},{"label":"Placebo + C5 Inhibitor","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: C5 Inhibitor"]}],"interventions":[{"name":"Danicopan","otherNames":["ALXN2040"]},{"name":"Placebo","otherNames":[]},{"name":"C5 Inhibitor","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of PNH\n* Clinically Evident EVH defined by:\n\n  * Anemia (Hgb ≤9.5 gram/deciliter) with absolute reticulocyte count ≥120 x 10\\^9/liter\n* Receiving an approved C5 inhibitor for at least 6 months prior to Day 1\n* Platelet count ≥30,000/microliters (µL)\n* Absolute neutrophil counts ≥500/μL\n* Documentation of/or willingness to receive vaccinations for N. meningiditis and prophylactic antibiotics as required\n\nExclusion Criteria:\n\n* History of a major organ transplant or hematopoietic stem cell transplantation (HSCT)\n* Participants with known aplastic anemia or other bone marrow failure that requires HSCT or other therapies including anti-thymocyte globulin and/or immunosuppressants\n* Known or suspected complement deficiency\n* Laboratory abnormalities at screening, including:\n\n  * Alanine aminotransferase \\>2 x ULN (\\>3 x ULN in case of patients with documented liver iron overload defined by serum ferratin values\n\n    * 500 ng/ML)\n  * Direct bilirubin \\>2 x ULN (unless due to EVH or documented Gilbert's Syndrome)\n* Current evidence of biliary cholestasis\n* Estimated glomerular filtration rate of \\<30 milliliters/minute/1.73 meter squared and/or are on dialysis\n* Evidence of human immunodeficiency virus, hepatitis B, or active hepatitis C infection at screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hgb at Week 12","description":"Baseline was defined as the lowest Hgb value observed between and including Screening and Day 1. The least square (LS) mean and standard error (SE) were produced using mixed-effect model for repeated measures (MMRM). Hgb values collected within 4 weeks after transfusion were not included in the MMRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.40","spread":"2.107"},{"groupId":"OG001","value":"4.96","spread":"3.128"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.08","spread":"1.957"},{"groupId":"OG001","value":"4.62","spread":"3.018"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hgb Increase of ≥2 Grams/Deciliter (g/dL) (≥20 g/L) From Baseline in the Absence of Transfusion at Week 12","description":"The criterion was defined as ≥20 g/L increase in Hgb from Baseline to Week 12 and remaining transfusion free during the 12-Week TP1. Participants who withdrew from the study early during the 12-Week TP1 or had missing Hgb value at Week 12 were considered as not achieving the criterion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Transfusion Avoidance Through Week 12","description":"Participants achieved transfusion avoidance if they remained transfusion free and did not require a transfusion as per protocol-specified guidelines from Week 1 through Week 12. Participants who discontinued study treatment early before Week 12 were considered as not achieving transfusion avoidance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"38.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"27.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score at Week 12","description":"The FACIT-Fatigue was 13-item questionnaire scored on a 5-point Likert scale (0 = not at all, 4 = very much) that assesses self-reported fatigue and its impact on daily activities and function. Total scores range from 0 to 52 with higher score indicating less fatigue and better health-related quality of life. LS mean and SE were produced using MMRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.97","spread":"1.128"},{"groupId":"OG001","value":"1.85","spread":"1.581"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.13","spread":"0.919"},{"groupId":"OG001","value":"2.35","spread":"1.289"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Absolute Reticulocyte Count at Week 12","description":"LS mean and SE were produced using MMRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0838","spread":"0.00893"},{"groupId":"OG001","value":"0.0035","spread":"0.01268"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0925","spread":"0.00816"},{"groupId":"OG001","value":"-0.0008","spread":"0.01184"}]}]}]},{"type":"SECONDARY","title":"Change in the Number of Red Blood Cell (RBC) Units Transfused From 24 Weeks Prior to Initiation of Treatment to Post 24 Weeks of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"4.86"}]}]}]},{"type":"SECONDARY","title":"Change in Number of Transfusion Instances From 24 Weeks Prior to Initiation of Treatment to Post 24 Weeks of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"2.41"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Transfusion Avoidance Through Week 24","description":"Participants achieved transfusion avoidance if they remained transfusion free and did not require a transfusion as per protocol-specified guidelines from Week 1 through Week 24. Participants who discontinued study treatment early before Week 24 were considered as not achieving transfusion avoidance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Number of RBC Units Transfused From 12 Weeks Prior to Initiation of Treatment to Post 12 Weeks of Treatment","description":"LS mean and SE were produced using analysis of covariance (ANCOVA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.48","spread":"0.271"},{"groupId":"OG001","value":"-0.18","spread":"0.383"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"0.212"},{"groupId":"OG001","value":"-0.14","spread":"0.297"}]}]}]},{"type":"SECONDARY","title":"Change in Number of Transfusion Instances From 12 Weeks Prior to Initiation of Treatment to Post 12 Weeks of Treatment","description":"LS mean and SE were produced using ANCOVA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.92","spread":"0.174"},{"groupId":"OG001","value":"-0.21","spread":"0.246"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":"0.138"},{"groupId":"OG001","value":"-0.11","spread":"0.193"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline FACIT Fatigue Scores at Week 24","description":"The FACIT-Fatigue was 13-item questionnaire scored on a 5-point Likert scale (0 = not at all, 4 = very much) that assesses self-reported fatigue and its impact on daily activities and function. Total scores range from 0 to 52 with higher score indicating less fatigue and better health-related quality of life. LS mean and SE were produced using MMRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.21","spread":"1.046"},{"groupId":"OG001","value":"5.64","spread":"1.921"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hgb Stabilization During Last 12 Weeks of Treatment in Participants Receiving 24 Weeks of Danicopan","description":"The criterion was defined as Hgb stabilization avoidance of a \\>1 g/dL (\\>10 g/L) decrease in Hgb level at Week 24 from Week 12. Participants with transfusions within 4 weeks prior to Week 24 were considered as not meeting Hgb stabilization regardless of the actual value observed at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hgb Increase of ≥2 g/dL (≥ 20 g/L) From Baseline in the Absence of Transfusion at Week 24","description":"The criterion was defined as ≥20 g/L increase in Hgb from Baseline to Week 24 and remaining transfusion free during the 12-Week TP2. Participants who withdrew from the study early during the 12-Week TP2 or had missing Hgb value at Week 24 were considered as not achieving the criterion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total and Direct Bilirubin at Week 12","description":"Baseline was defined as the last non-missing value prior to first dose of study intervention. LS mean and SE were produced using MMRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.77","spread":"1.692"},{"groupId":"OG001","value":"-2.15","spread":"2.377"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.88","spread":"0.357"},{"groupId":"OG001","value":"0.30","spread":"0.503"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.55","spread":"1.541"},{"groupId":"OG001","value":"-1.42","spread":"2.172"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.85","spread":"0.317"},{"groupId":"OG001","value":"0.17","spread":"0.447"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Paroxysmal Nocturnal Hemoglobinuria (PNH) RBC Clone Size at Week 12","description":"The PNH clone size refers to the percentage of PNH-affected cells versus normal cells within the total cell population. Baseline was defined as the last non-missing value prior to first dose of study intervention. LS mean and SE were produced using MMRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.60","spread":"4.180"},{"groupId":"OG001","value":"-3.04","spread":"5.864"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.35","spread":"2.369"},{"groupId":"OG001","value":"-0.18","spread":"2.960"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Complement Component 3 Fragment Deposition (C3d PNH Type 3 Cells) on PNH RBCs at Week 12","description":"Baseline was defined as the last non-missing value prior to first dose of study intervention. LS mean and SE were produced using MMRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.06","spread":"2.824"},{"groupId":"OG001","value":"0.89","spread":"4.394"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.00","spread":"1.814"},{"groupId":"OG001","value":"0.68","spread":"2.690"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lactate Dehydrogenase at Week 12","description":"Baseline was defined as the average of all available assessments prior to the first dose of study intervention. LS mean and SE were produced using MMRM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.49","spread":"8.287"},{"groupId":"OG001","value":"-2.92","spread":"11.914"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.60","spread":"7.932"},{"groupId":"OG001","value":"-16.92","spread":"11.380"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hgb Normalization at Week 12","description":"Hgb normalization was defined as Hgb value above lower limit of normal (LLN) reference range. For male, the LLN was 125 g/L, for female, the LLN was 110 g/L. Participants with transfusions within 4 weeks prior to Week 12 were considered as not meeting Hgb normalization regardless of actual value observed at Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hgb Normalization at Week 24","description":"Hgb normalization was defined as Hgb value above LLN reference range. For male, the LLN was 125 g/L, for female, the LLN was 110 g/L. Participants with transfusions within 4 weeks prior to Week 24 were considered as not meeting Hgb normalization regardless of actual value observed at Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":57},"commonTop":["Pyrexia","Headache","COVID-19","Diarrhoea","Nausea"]}}}